Gavin Sathianathan's guest appearances

Gavin Sathianathan

The Cannabis Conversation | Medical Cannabis | CBD | Hemp

The Oxford Biotech Podcast

Neil Mahapatra

Matt Brown

Nick Davis

Colin Morgan

Chris Kelly

Bruce Linton

Steve DeAngelo

Chris Walsh

Alan Brochstein

Montel Williams

Vanmala Subramaniam

Bonni Goldstein

George Kruis

Michael Patterson

Rebecca Moore

OwlTail

We’ve reached episode 50! What a journey it’s been. In the last 50 episodes we’ve covered a range of topics across medical cannabis, CBD and hemp including extraction, the vaping crisis, mental health, multi state operators, sustainability, entrepreneurship, cultivation and banking! In this very special episode of The Cannabis Conversation, we’re joined by Gavin Sathianathan, CEO at Alta Flora. Join us as we discuss cannabis and patient data, differing attitudes towards cannabis in North American and European markets, and personalised medicine.About GavinGavin Sathianathan is a serial entrepreneur and acknowledged leader in the cannabis industry, and serves as CEO of Alta Flora, a tech company focused on improving quality of life through better understanding the relationship between an individual patient and medical cannabis. Gavin started his cannabis industry experience in 2014, initially in the US where he acquired, operated and sold a medical cannabis dispensary business in Las Vegas, Nevada. In 2017, seeing movement in the European legislative and regulatory frameworks, Gavin returned to Europe and has established a number of ventures. In addition to his role as CEO of Alta Flora, Gavin serves on the boards of Oxford Cannabinoid Technologies, Grass &amp; Co. and Product Earth. Gavin is also a Trustee of the United Patients Alliance and is an advisor to multiple FTSE 100 companies. Gavin has a degree in Chemical Engineering from Imperial College and an MBA from Harvard Business SchoolEpisode SummaryGavin’s trained as a chemical engineer, but later on went to work in digital and mobile technology. David has worked for companies including Tesco, Endemol and Facebook.In 2015 Gavin decided to join the cannabis space, relocating his family to Boulder, Colorado.Gavin started his journey in the USA by investing in Californian cannabis companies and later on running a dispensary in Las Vegas. Gavin closed up shop in the USA as Donald Trump became president and moved back to the UK, starting and co-founding more businesses within the space including Oxford Cannabinoid Technologies.In 2018, Gavin started Alta Flora - wellness product manufacturer which aims to improve health and wellbeing through technology enabled solutions.Gavin sits on the board of Product Earth Expo UK, ( the UK’s longest running cannabis CBD and help trade show) alongside Grass &amp; Co, botanical wellness business.Gavin notes that on the west coast of the USA, from Alaska to Mexico, cannabis is widely accepted and is able to be purchased in dispensaries. On the eastern coast, cannabis is on a journey from ‘medicine to lifestyle’ with many states now legalising use.In Europe, we are on a journey from ‘drug to medicine’.Cannabis is widely ingrained into American culture, with characters in TV shows having medical cannabis cards, to its prevalence in Billboard 100 music.Gavin believes that the era of 20th century mass produced medicines will end and in its place we will see individualised medication systems.Alta Flora has built an app which allows patients to log their interactions and consumption of cannabis. This allows a quantifiable insight into consumption which is data backed.Cannabis is regulated in Europe as a medicine, whereas in North America its regulation draws more parallels with the tobacco and alcohol industries.Your body will process cannabinoids differently depending on how much you have slept, what you have eaten, and how much exercise you have had amongst other factors.Gavin believes that the European market is fundamentally different. Some of these differences are:European regulatory models come from the pharmaceutical industry whereas in North America they come from the tobacco and alcohol industries.  

We’ve reached episode 50! What a journey it’s been. In the last 50 episodes we’ve covered a range of topics across medical cannabis, CBD and hemp including extraction, the vaping crisis, mental health, multi state operators, sustainability, entrepreneurship, cultivation and banking! In this very special episode of The Cannabis Conversation, we’re joined by Gavin Sathianathan, CEO at Alta Flora. Join us as we discuss cannabis and patient data, differing attitudes towards cannabis in North American and European markets, and personalised medicine. <h1>About Gavin</h1> Gavin Sathianathan is a serial entrepreneur and acknowledged leader in the cannabis industry, and serves as CEO of Alta Flora, a tech company focused on improving quality of life through better understanding the relationship between an individual patient and medical cannabis. Gavin started his cannabis industry experience in 2014, initially in the US where he acquired, operated and sold a medical cannabis dispensary business in Las Vegas, Nevada. In 2017, seeing movement in the European legislative and regulatory frameworks, Gavin returned to Europe and has established a number of ventures. In addition to his role as CEO of Alta Flora, Gavin serves on the boards of Oxford Cannabinoid Technologies, Grass &amp; Co. and Product Earth. Gavin is also a Trustee of the United Patients Alliance and is an advisor to multiple FTSE 100 companies. Gavin has a degree in Chemical Engineering from Imperial College and an MBA from Harvard Business School<h1> Episode Summary</h1><ul><li>Gavin’s trained as a chemical engineer, but later on went to work in digital and mobile technology. David has worked for companies including Tesco, Endemol and Facebook.</li><li>In 2015 Gavin decided to join the cannabis space, relocating his family to Boulder, Colorado.</li><li>Gavin started his journey in the USA by investing in Californian cannabis companies and later on running a dispensary in Las Vegas. </li><li>Gavin closed up shop in the USA as Donald Trump became president and moved back to the UK, starting and co-founding more businesses within the space including Oxford Cannabinoid Technologies.</li><li>In 2018, Gavin started Alta Flora - wellness product manufacturer which aims to improve health and wellbeing through technology enabled solutions.</li><li>Gavin sits on the board of Product Earth Expo UK, ( the UK’s longest running cannabis CBD and help trade show) alongside Grass &amp; Co, botanical wellness business.</li><li>Gavin notes that on the west coast of the USA, from Alaska to Mexico, cannabis is widely accepted and is able to be purchased in dispensaries. On the eastern coast, cannabis is on a journey from ‘medicine to lifestyle’ with many states now legalising use.</li><li>In Europe, we are on a journey from ‘drug to medicine’.</li><li>Cannabis is widely ingrained into American culture, with characters in TV shows having medical cannabis cards, to its prevalence in Billboard 100 music.</li><li>Gavin believes that the era of 20th century mass produced medicines will end and in its place we will see individualised medication systems.</li><li>Alta Flora has built an app which allows patients to log their interactions and consumption of cannabis. This allows a quantifiable insight into consumption which is data backed.</li><li>Cannabis is regulated in Europe as a medicine, whereas in North America its regulation draws more parallels with the tobacco and alcohol industries.</li><li>Your body will process cannabinoids differently depending on how much you have slept, what you have eaten, and how much exercise you have had amongst other factors.</li><li>Gavin believes that the European market is fundamentally different. Some of these differences are:</li><li>European regulatory models come from the pharmaceutical industry whereas in North America they come from the tobacco and alcohol industries. </li><li> </li></ul>

EPISODE #50 Cannabis and Patient Data with Gavin Sathianathan, CEO at Alta Flora

Medical cannabis is expected to reach 56.7B market value by 2026. On this episode we hear from Oxford Cannabinoid Technologies co-founders Neil Mahapatra (Kingsley Capital Partners, Rothschild, Morgan Stanley) and Gavin Sathianathan (Alta Flora, Facebook, Bain) about their use of technological advances and a network innovation model to develop patient-saving pharmaceuticals from cannabis.  Music from: https://freesound.org/   OCT: https://www.oxcantech.com/

Medical cannabis is expected to reach 56.7B market value by 2026. On this episode we hear from Oxford Cannabinoid Technologies co-founders Neil Mahapatra (Kingsley Capital Partners, Rothschild, Morgan Stanley) and Gavin Sathianathan (Alta Flora, Facebook, Bain) about their use of technological advances and a network innovation model to develop patient-saving pharmaceuticals from cannabis.  Music from: <a href="https://freesound.org/" rel="nofollow" target="_blank">https://freesound.org/ </a>  OCT: <a href="https://www.oxcantech.com/" rel="nofollow" target="_blank">https://www.oxcantech.com/</a>

Medical Cannabis: Oncology and Pain Game Changer, or just a Pipe Dream? With OCT Founders Gavin Sathianathan and Neil Mahapatra.